LU87516A1 - Utilisation de derives de la gonadoliberine pour preparer des compositions pharmaceutiques anti-tumorales - Google Patents
Utilisation de derives de la gonadoliberine pour preparer des compositions pharmaceutiques anti-tumorales Download PDFInfo
- Publication number
- LU87516A1 LU87516A1 LU87516A LU87516A LU87516A1 LU 87516 A1 LU87516 A1 LU 87516A1 LU 87516 A LU87516 A LU 87516A LU 87516 A LU87516 A LU 87516A LU 87516 A1 LU87516 A1 LU 87516A1
- Authority
- LU
- Luxembourg
- Prior art keywords
- group
- general formula
- hormone
- gnrh
- tumors
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 15
- 108050000048 Gonadoliberin Proteins 0.000 title claims description 8
- 102000009165 Gonadoliberin Human genes 0.000 title claims description 8
- 230000000259 anti-tumor effect Effects 0.000 title description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 24
- 229940088597 hormone Drugs 0.000 claims description 18
- 239000005556 hormone Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 16
- 230000001419 dependent effect Effects 0.000 claims description 13
- 230000008569 process Effects 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 7
- 230000003054 hormonal effect Effects 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 5
- 150000008575 L-amino acids Chemical group 0.000 claims description 4
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
- 150000008574 D-amino acids Chemical group 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 125000003368 amide group Chemical group 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 150000004696 coordination complex Chemical class 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 125000001998 leucyl group Chemical group 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 125000001982 tryptophyl group Chemical group 0.000 claims description 2
- -1 alkanoyl amide Chemical class 0.000 claims 1
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical group NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 20
- 230000000694 effects Effects 0.000 description 14
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 206010006187 Breast cancer Diseases 0.000 description 11
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 208000026310 Breast neoplasm Diseases 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 230000016087 ovulation Effects 0.000 description 9
- 241000124008 Mammalia Species 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 230000010534 mechanism of action Effects 0.000 description 8
- 230000002611 ovarian Effects 0.000 description 8
- 210000001672 ovary Anatomy 0.000 description 8
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 150000003431 steroids Chemical class 0.000 description 7
- 241000251468 Actinopterygii Species 0.000 description 6
- 102000006771 Gonadotropins Human genes 0.000 description 6
- 108010086677 Gonadotropins Proteins 0.000 description 6
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
- 238000000586 desensitisation Methods 0.000 description 6
- 235000019688 fish Nutrition 0.000 description 6
- 239000002622 gonadotropin Substances 0.000 description 6
- 229940094892 gonadotropins Drugs 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 230000004614 tumor growth Effects 0.000 description 6
- 241000972773 Aulopiformes Species 0.000 description 5
- 241000287828 Gallus gallus Species 0.000 description 5
- 206010062767 Hypophysitis Diseases 0.000 description 5
- 230000003325 follicular Effects 0.000 description 5
- 230000002710 gonadal effect Effects 0.000 description 5
- 230000035800 maturation Effects 0.000 description 5
- 210000003635 pituitary gland Anatomy 0.000 description 5
- 229960003387 progesterone Drugs 0.000 description 5
- 239000000186 progesterone Substances 0.000 description 5
- 235000019515 salmon Nutrition 0.000 description 5
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229960005309 estradiol Drugs 0.000 description 4
- 229930182833 estradiol Natural products 0.000 description 4
- 210000002149 gonad Anatomy 0.000 description 4
- 230000001817 pituitary effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- ARSRBNBHOADGJU-UHFFFAOYSA-N 7,12-dimethyltetraphene Chemical compound C1=CC2=CC=CC=C2C2=C1C(C)=C(C=CC=C1)C1=C2C ARSRBNBHOADGJU-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical class C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000001850 reproductive effect Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 229960003604 testosterone Drugs 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- VFZRZRDOXPRTSC-UHFFFAOYSA-N DMBA Natural products COC1=CC(OC)=CC(C=O)=C1 VFZRZRDOXPRTSC-UHFFFAOYSA-N 0.000 description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 2
- 108010069236 Goserelin Proteins 0.000 description 2
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 2
- 102100033467 L-selectin Human genes 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 229940028334 follicle stimulating hormone Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940040129 luteinizing hormone Drugs 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 230000021595 spermatogenesis Effects 0.000 description 2
- 239000003270 steroid hormone Substances 0.000 description 2
- 230000010009 steroidogenesis Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 206010060999 Benign neoplasm Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
- 125000000734 D-serino group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 125000002435 L-phenylalanyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000002707 L-tryptophyl group Chemical group [H]C1=C([H])C([H])=C2C(C([C@](N([H])[H])(C(=O)[*])[H])([H])[H])=C([H])N([H])C2=C1[H] 0.000 description 1
- 102000008238 LHRH Receptors Human genes 0.000 description 1
- 108010021290 LHRH Receptors Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 108010085012 Steroid Receptors Proteins 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 210000004246 corpus luteum Anatomy 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000005002 female reproductive tract Anatomy 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 101150108262 gnrh1 gene Proteins 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 230000004185 hypothalamic-pituitary-gonadal axis Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000029849 luteinization Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000021121 meiosis Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000002394 ovarian follicle Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000004800 psychological effect Effects 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 230000035938 sexual maturation Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229940033942 zoladex Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU882347A HU199694B (en) | 1988-05-10 | 1988-05-10 | Process for producing citostatic pharmaceutical compositions containing gonadoliberin derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LU87516A1 true LU87516A1 (fr) | 1990-12-11 |
Family
ID=10958948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU87516A LU87516A1 (fr) | 1988-05-10 | 1989-05-10 | Utilisation de derives de la gonadoliberine pour preparer des compositions pharmaceutiques anti-tumorales |
Country Status (16)
| Country | Link |
|---|---|
| JP (1) | JPH0215097A (de) |
| KR (1) | KR900017610A (de) |
| BE (1) | BE1004932A3 (de) |
| CH (1) | CH678013A5 (de) |
| DE (1) | DE3915317A1 (de) |
| DK (1) | DK228289A (de) |
| FI (1) | FI892275A7 (de) |
| FR (1) | FR2631237A1 (de) |
| GB (1) | GB2218335B (de) |
| GR (1) | GR890100315A (de) |
| HU (1) | HU199694B (de) |
| IL (1) | IL89998A0 (de) |
| IT (1) | IT1229251B (de) |
| LU (1) | LU87516A1 (de) |
| NL (1) | NL8901159A (de) |
| SE (1) | SE8901660L (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5760000A (en) * | 1994-05-13 | 1998-06-02 | University Technologies International,Inc. | Inhibition of liver cancer by the use of GnRH and GnRH analogs |
| US6054432A (en) * | 1996-09-12 | 2000-04-25 | Asta Medica Aktiengesellschaft | Means for treating prostate hypertrophy and prostate cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4410514A (en) * | 1982-12-06 | 1983-10-18 | The Salk Institute For Biological Studies | GnRH Agonists |
| IT1178775B (it) * | 1983-12-23 | 1987-09-16 | Konzponti Valto Es Hitelbank R | Derivati della gonadoliberina e procedimento per la loro preparazione |
| HU189394B (en) * | 1983-12-23 | 1986-06-30 | Koezponti Valto- Es Hitelbank Rt Innovacios Alap,Hu | Method for producing spermatozoa suitable for fertilization from mature fishes |
| IE58836B1 (en) * | 1984-08-02 | 1993-11-17 | Labrie Fernand | Pharmaceutical composition for combination therapy of hormone dependent cancers |
| US4760053A (en) * | 1984-08-02 | 1988-07-26 | Fernand Labrie | Combination therapy for selected sex steroid dependent cancers |
| HU193607B (en) * | 1985-07-18 | 1987-11-30 | Innofinance Altalanos Innovaci | Process for production of sexual products applyable for natural or artificial insemination for mammates |
| US4721775A (en) * | 1985-08-26 | 1988-01-26 | Board Of Regents, The University Of Texas System | Effective peptides related to the luteinizing hormone releasing hormone from L-amino acids |
| HU194913B (en) * | 1986-01-03 | 1988-03-28 | Innofinance Altalanos Innovaci | Process for producing novel gonadoliberin derivatives containing in the sixth position aromatic amino carboxylic acid and medical preparations containing these compounds |
-
1988
- 1988-05-10 HU HU882347A patent/HU199694B/hu active IP Right Revival
-
1989
- 1989-04-18 IL IL89998A patent/IL89998A0/xx unknown
- 1989-05-08 CH CH1725/89A patent/CH678013A5/de not_active IP Right Cessation
- 1989-05-09 NL NL8901159A patent/NL8901159A/nl not_active Application Discontinuation
- 1989-05-10 JP JP1115265A patent/JPH0215097A/ja active Pending
- 1989-05-10 KR KR1019890006230A patent/KR900017610A/ko not_active Withdrawn
- 1989-05-10 GR GR890100315A patent/GR890100315A/el unknown
- 1989-05-10 SE SE8901660A patent/SE8901660L/ not_active Application Discontinuation
- 1989-05-10 DK DK228289A patent/DK228289A/da not_active Application Discontinuation
- 1989-05-10 BE BE8900499A patent/BE1004932A3/fr not_active IP Right Cessation
- 1989-05-10 GB GB8910724A patent/GB2218335B/en not_active Expired - Fee Related
- 1989-05-10 LU LU87516A patent/LU87516A1/fr unknown
- 1989-05-10 FI FI892275A patent/FI892275A7/fi not_active Application Discontinuation
- 1989-05-10 DE DE3915317A patent/DE3915317A1/de not_active Withdrawn
- 1989-05-10 FR FR8906094A patent/FR2631237A1/fr active Pending
- 1989-05-11 IT IT8920435A patent/IT1229251B/it active
Also Published As
| Publication number | Publication date |
|---|---|
| DK228289A (da) | 1989-11-11 |
| GB2218335B (en) | 1991-09-25 |
| NL8901159A (nl) | 1989-12-01 |
| FI892275A0 (fi) | 1989-05-10 |
| CH678013A5 (de) | 1991-07-31 |
| KR900017610A (ko) | 1990-12-19 |
| DE3915317A1 (de) | 1989-11-23 |
| IL89998A0 (en) | 1989-12-15 |
| JPH0215097A (ja) | 1990-01-18 |
| SE8901660L (sv) | 1989-11-11 |
| IT8920435A0 (it) | 1989-05-11 |
| HUT49813A (en) | 1989-11-28 |
| HU199694B (en) | 1990-03-28 |
| IT1229251B (it) | 1991-07-26 |
| GB8910724D0 (en) | 1989-06-28 |
| DK228289D0 (da) | 1989-05-10 |
| SE8901660D0 (sv) | 1989-05-10 |
| GR890100315A (el) | 1990-03-12 |
| BE1004932A3 (fr) | 1993-03-02 |
| FR2631237A1 (fr) | 1989-11-17 |
| FI892275A7 (fi) | 1989-11-11 |
| GB2218335A (en) | 1989-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Breton et al. | GTH I and GTH II secretion profiles during the reproductive cycle in female rainbow trout: relationship with pituitary responsiveness to GnRH-A stimulation | |
| Veldhuis | Gender differences in secretory activity of the human somatotropic (growth hormone) axis | |
| Bergendahl et al. | Effect of short-term starvation on reproductive hormone gene expression, secretion and receptor levels in male rats | |
| De Leeuw et al. | The regulation of gonadotropin release by neurohormones and gonadal steroids in the African catfish, Clarias gariepinus | |
| Sower | The endocrinology of reproduction in lampreys and applications for male lamprey sterilization | |
| Tannenbaum et al. | Tamoxifen attenuates pulsatile growth hormone secretion: mediation in part by somatostatin. | |
| Meijs-Roelofs et al. | Maturation of the inhibitory feedback action of oestrogen on follicle-stimulating hormone secretion in the immature female rat: a role for alpha-foetoprotein | |
| Licht et al. | Somatotropic effects of exogenous prolactin and growth hormone in juvenile lizards (Lacerta s. sicula) | |
| Moszkowska et al. | The influence of the pineal body on the gonadotropic function of the hypophysis | |
| BE1004932A3 (fr) | Utilisation de derives de la gonadoliberine pour preparer des compositions pharmaceutiques anti-tumorales. | |
| HU226567B1 (en) | Use of phenylhydrazon derivates for the preparation of medicaments for the inhibition of neurogenic and non-neurogenic inflammations and for the alleviation of pain | |
| KR20180137605A (ko) | 남성 불임을 치료하기 위한 ｄ－아스파르트산 및 ｌ－아스파르트산 또는 이들 염의 조합체의 용도 | |
| HU189394B (en) | Method for producing spermatozoa suitable for fertilization from mature fishes | |
| Xiao et al. | Cysteamine—a somatostatin-inhibiting agent—induced growth hormone secretion and growth acceleration in juvenile grass carp (Ctenopharyngodon idellus) | |
| Holloway et al. | The Effects ofN-Methyl-d, l-aspartate and Gonadotropin-Releasing Hormone onin VitroGrowth Hormone Release in Steroid-Primed Immature Rainbow Trout, Oncorhynchus mykiss | |
| ADAMS et al. | Suppression of Plasma Gonadotropins and Testosterone in Adult Male Monke (Macaca fascicularis) by a Potent Inhibitory Analog of Gonadotropin-Releasing Hormone | |
| Bellido et al. | Possible role of changes in post-natal gonadotrophin concentrations on permanent impairment of the reproductive system in neonatally oestrogenized male rats | |
| EP1680139A2 (de) | Verwendung von somatostatin oder einem der analoga zur herstellung eines medikaments zur regulierung der eierstock-follikel-reserve in nicht-menopausalen frauen | |
| Van Tienhoven | Neuroendocrinology of avian reproduction, with special emphasis on the reproductive cycle of the fowl (Gallus domesticus) | |
| DAHL et al. | The ultrastructure of the accessory sex organs of the male rat: the effect of cyproterone acetate | |
| Horvath et al. | Ganglion cells in the posterior pituitary: result of ectopia or transdifferentiation? | |
| JP2700595B2 (ja) | アゾール誘導体を含有する抗アロマターゼ剤 | |
| Celotti et al. | Is the 5α-reductase of the hypothalamus and of the anterior pituitary neurally regulated?: Effects of hypothalamic deafferentations and of centrally acting drugs | |
| Gottesfeld et al. | Fetal alcohol exposure and adult tumorigenesis | |
| ONAYA et al. | Altered responsiveness to thyrotropin in thyroid slices of Graves' disease preoperatively treated with excess iodide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DT | Application date | ||
| TA | Annual fee |